Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 3INTERVENTIONAL

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

Who May Be Eligible (Plain English)

Who May Qualify: - Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH - Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH Who Should NOT Join This Trial: - Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results - Type 1 diabetes or unstable Type 2 diabetes - Any current or prior history of decompensated liver disease Other inclusion and exclusion criteria may apply Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH * Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH Exclusion Criteria: * Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results * Type 1 diabetes or unstable Type 2 diabetes * Any current or prior history of decompensated liver disease Other inclusion and exclusion criteria may apply

Treatments Being Tested

DRUG

Efruxifermin

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Locations (20)

Akero Clinical Study Site
Birmingham, Alabama, United States
Akero Clinical Study Site
Dothan, Alabama, United States
Akero Clinical Study Site
Chandler, Arizona, United States
Akero Clinical Study Site
Flagstaff, Arizona, United States
Akero Clinical Study Site
Peoria, Arizona, United States
Akero Clinical Study Site
Scottsdale, Arizona, United States
Akero Clinical Study Site
Tucson, Arizona, United States
Akero Clinical Study Site
Tucson, Arizona, United States
Akero Clinical Study Site
Tucson, Arizona, United States
Akero Clinical Study Site
Tucson, Arizona, United States
Akero Clinical Study Site
Conway, Arkansas, United States
Akero Clinical Study Site
Jonesboro, Arkansas, United States
Akero Clinical Study Site
Little Rock, Arkansas, United States
Akero Clinical Study Site
North Little Rock, Arkansas, United States
Akero Clinical Study Site
Coronado, California, United States
Akero Clinical Study Site
Escondido, California, United States
Akero Clinical Study Site
Folsom, California, United States
Akero Clinical Study Site
Lancaster, California, United States
Akero Clinical Study Site
Long Beach, California, United States
Akero Clinical Study Site
Los Angeles, California, United States